Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29342015 | 0.87 | GRM2 (0.44) | GRM2HTR2AHTR2CAPAF1POLB | |
| SCHEMBL19911624 | 0.81 | GRM2 (0.47) | GRM2HTR2AHTR2CHCAR3KCNMA1 | |
| SCHEMBL18323591 | 0.81 | HCAR3 (0.58) | GRM2POLBHCAR3NPC1RAB9A | |
| SCHEMBL19848301 | 0.79 | HCAR3 (0.60) | GRM2POLBHCAR3ALDH1A1SLC9A1 | |
| SCHEMBL19848324 | 0.77 | HCAR3 (0.45) | GRM2POLBHCAR3NPC1RAB9A | |
| SCHEMBL19848730 | 0.76 | SLC9A1 (0.62) | GRM2HCAR3SMN1; SMN2ALDH1A1SLC9A1 | |
| SCHEMBL7716431 | 0.76 | APAF1 (0.67) | GRM2APAF1POLBNPC1RAB9A | |
| SCHEMBL23084792 | 0.76 | HCAR3 (0.72) | APAF1POLBHCAR3 | |
| SCHEMBL19911617 | 0.75 | HCAR3 (0.58) | HTR2AHTR2CHCAR3SMN1; SMN2KCNMA1 | |
| SCHEMBL19848744 | 0.74 | GRM2 (0.42) | GRM2HCAR3RAB9ASMN1; SMN2KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | GRM2 3597/4885HTR2A 2198/4885HTR2C 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.